A Multicenter Study to Assess the Safety and Cardiovascular Effects of Myocell Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s)
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 04 Jul 2019
Price : $35 *
At a glance
- Drugs Muscle-derived autologous stem cell therapy Bioheart (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms MARVEL
- Sponsors U.S. Stem Cell
- 20 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2019.
- 26 Jan 2015 According to the ClinicalTrials.gov record, planned changed from 1 Feb 2012 to 1 Feb 2017.
- 26 Jan 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Feb 2014 to 1 Feb 2017.